Navigation Links
Pharmasset Receives Notice of Allowance
Date:6/26/2008

-USPTO to grant patent covering the anti-HCV drug PSI-6130 and its active

metabolites

PRINCETON, N.J., June 26 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application Serial No. 10/828,753 titled, "Modified Fluorinated Nucleoside Analogues," covering the composition of matter of a family of molecules invented at Pharmasset for the treatment of hepatitis C virus (HCV), including PSI-6130 and the active metabolite of PSI-7851. R7128, a prodrug of PSI-6130, a nucleoside analogue polymerase inhibitor of HCV, is being developed through Pharmasset's collaboration with Roche. PSI-7851 is a proprietary nucleotide analogue polymerase inhibitor of HCV that Pharmasset has nominated as a lead development candidate.

"We are pleased that the USPTO has recognized our intellectual property rights in our growing pipeline of HCV nucleoside polymerase inhibitors," stated Schaefer Price, Pharmasset's Chief Executive Officer. "The success that our in-house research team has had in discovering new HCV product candidates can now be translated into potentially significant commercial value."

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 /CNW/ - Atlantic Canadians will ... reached between Canada,s provinces and ... , President of the Canadian Generic Pharmaceutical Association (CGPA), ... comments while speaking at the Atlantic Summit on Healthcare ... , which is being hosted by the Public Policy ...
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
... NEW YORK, March 24, 2011 Reportlinker.com announces ... in its catalogue: Assistive Devices ... http://www.reportlinker.com/p0461658/Assistive-Devices-for-Special-Needs-Technologies-and-Global-Markets.html ... of devices and accommodation products for several categories ...
... NEW YORK, March 24, 2011 Reportlinker.com announces that ... catalogue: Therapeutics for Immune System ... In 2010, the global market for drugs for ... approximately $72.2 billion.  The market size is forecast to ...
Cached Medicine Technology:Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 2Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 3Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 4Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 5Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 6Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 7Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 8Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 9Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 10Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 11Reportlinker Adds Therapeutics for Immune System Disorders 2Reportlinker Adds Therapeutics for Immune System Disorders 3Reportlinker Adds Therapeutics for Immune System Disorders 4Reportlinker Adds Therapeutics for Immune System Disorders 5Reportlinker Adds Therapeutics for Immune System Disorders 6Reportlinker Adds Therapeutics for Immune System Disorders 7Reportlinker Adds Therapeutics for Immune System Disorders 8Reportlinker Adds Therapeutics for Immune System Disorders 9Reportlinker Adds Therapeutics for Immune System Disorders 10Reportlinker Adds Therapeutics for Immune System Disorders 11Reportlinker Adds Therapeutics for Immune System Disorders 12Reportlinker Adds Therapeutics for Immune System Disorders 13
(Date:10/31/2014)... October 31, 2014 Springboard Biodiesel, ... its small scale BioPro™ biodiesel processors, announced on ... further improve the performance and efficiency of small-scale ... GL95/MC12/BD380 trio will recover more than 99% ... with the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 At ... country about families narrowly escaping carbon monoxide poisoning in ... looms just weeks away, one family-owned, Missouri-based heating and ... approach to making sure families start the home heating ... safe and secure. , Beginning Nov. 1, 2014, ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... ANN ARBOR, Mich. The use of a pedometer and ... be powerful motivators for people with diabetes who participated in ... of Michigan Health System and VA Ann Arbor Healthcare System. ... be more effective than others. , All participants in the ...
... November 19, 2007Health care providers, insurance companies and drug ... public, according to a new survey of leaders in ... Healthcare Health Care Opinion Leaders Survey finds widespread support ... provider quality and prices, 86 percent of respondents support ...
... most harmful strains of human papillomavirus is under study ... called nine-valent, is being compared with Gardasil, a quadrivalent ... two most deadly HPV types. , Were testing Gardasil ... Dr. Daron Ferris, family medicine physician and director of ...
... Eating disorders in the U.S. among ethnic groups were ... that many cultures are now exposed to the thin ... an increase in eating disorder symptoms among ethnic groups. ... control behaviors may be increasing among adolescent boys. ...
... that in cell cultures, the stress hormone norepinephrine appears ... cells to grow and spread. , The finding, ... progression and spread of some cancers enough so that ... work. , The study also showed that stress ...
... Nov. 19 ARJO, Inc. USA announces the,opening ... Coast showroom in Costa Mesa,(Orange County) California. The ... evaluate ARJO Extended Care Products,GETINGE Infection Control and ... (CS) settings. MAQUET Surgical Workplace products, for ...
Cached Medicine News:Health News:Pedometers motivate people with diabetes to walk more 2Health News:Pedometers motivate people with diabetes to walk more 3Health News:Health care opinion leaders support public reporting of health care quality, prices 2Health News:Health care opinion leaders support public reporting of health care quality, prices 3Health News:New HPV vaccine under study 2Health News:Eating disorders in adolescents 2Health News:Eating disorders in adolescents 3Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3Health News:ARJO / Getinge / Maquet Announces New West Coast Showroom Opening 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: